Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Pepparedsleden 1, Mölndal,västra Götaland 43183,sweden
- Phone
- +46 70 428 26 56
- in****@****ova.com
- Industry
- Biotechnology
- Website
- alzinova.com
- Keywords
- in Alzheimer’s and vaccine studies.
- HQ
- Mölndal, Västra Götaland
Alzinova Ab Questions
Alzinova Ab's helpline number is +46 70 428 26 56
Alzinova Ab's website is alzinova.com
Alzinova Ab's LinkedIn profile is https://se.linkedin.com/company/alzinova-ab
Alzinova Ab has
9 employees.
View email and phone details for 9
employees at Alzinova Ab.
Alzinova Ab's industry is
Biotechnology
Alzinova Ab's top competitors are
Alligator Bioscience Ab,
Affibody Ab,
Elicera Therapeutics Ab,
Alzecure Pharma,
Anocca,
Irlab Therapeutics Ab,
Bioarctic,
Biolamina,
Cereno Scientific,
Northx Biologics.
Alzinova Ab's support email address is info@alzinova.com
Alzinova Ab's categories are Biotechnology
Alzinova Ab's founding year is 2011
